Literature DB >> 10723092

Regulation of alphaVbeta3 and alphaVbeta5 integrins by dexamethasone in normal human osteoblastic cells.

S L Cheng1, C F Lai, A Fausto, M Chellaiah, X Feng, K P McHugh, S L Teitelbaum, R Civitelli, K A Hruska, F P Ross, L V Avioli.   

Abstract

Long-term administration of pharmacological doses of glucocorticoids inhibits bone formation and results in osteoporosis. Since integrin-mediated cell-matrix interactions are essential for osteoblast function, we hypothesized that the detrimental effect of glucocorticoids on bone derived, at least in part, from decreased integrin-matrix interactions. Because alphavbeta3 and alphavbeta5 integrins can interact with several bone matrix proteins, we analyzed the effects of dexamethasone (Dex) on the expression of these integrins in normal human osteoblastic cells. We found adhesion of these cells to osteopontin and vitronectin to be dependent on alphavbeta3 and alphavbeta5, respectively; this ligand specificity was not altered by Dex. The effects of Dex on the adhesion of human osteoblastic cells to osteopontin and vitronectin were biphasic with an increase after 2 days, followed by a decrease after 8 days of treatment. Consistently, surface alphavbeta3 and alphavbeta5 integrins, which were increased after 2 days of Dex treatment, were decreased after 8 days. Similarly, total cellular alphav, beta3, and beta5 proteins, which were increased by Dex early in the culture, were diminished after 8 days. Metabolic labeling studies indicated that Dex exhibited biphasic regulation on the biosynthesis of alphavbeta5, with stimulation observed during the second day of treatment, followed by inhibition during the 8th day of exposure. By contrast, the biosynthesis of alphavbeta3 was inhibited by Dex on day 1 and remained inhibited on day 8. Analysis of the mRNA indicated that alphav and beta5 levels were increased by Dex during early exposure (1-3 days), followed by inhibition after prolonged exposure (>/=7 days). By contrast, Dex decreased beta3 mRNA level at all the time points analyzed. Consistently, Dex decreased beta3 promoter activity after 1 day and persisted over 8-day period. By contrast, Dex stimulated beta5 promoter activity after 1 or 2 days but had no effect after 8 days. To further evaluate mechanism(s) leading to the decreased integrin expression after prolonged Dex treatment, mRNA stability was analyzed. Dex was found to accelerate the degradation of alphav, beta3 and beta5 mRNA after an 8-day treatment. Thus, the regulation of alphavbeta3 was dependent on transcription and posttranscriptional events whereas the expression of alphavbeta5 was dependent mainly on posttranscriptional events after prolonged Dex treatment. In conclusion, Dex exhibited time-dependent regulation on the expression of alphavbeta3 and alphavbeta5 integrins in normal human osteoblastic cells. Short-term exposure to Dex increased the levels of alphavbeta3 and alphavbeta5 on the surface and cell adhesion to osteopontin and vitronectin whereas long-term exposure to Dex decreased the expression of both integrins and inhibited the cell adhesion to matrix proteins. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10723092     DOI: 10.1002/(sici)1097-4644(20000501)77:2<265::aid-jcb9>3.0.co;2-6

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  19 in total

Review 1.  The role of alpha(v)beta(3) in prostate cancer progression.

Authors:  Carlton R Cooper; Christopher H Chay; Kenneth J Pienta
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Tailored integrin-extracellular matrix interactions to direct human mesenchymal stem cell differentiation.

Authors:  Jessica Ellen Frith; Richard James Mills; James Edward Hudson; Justin John Cooper-White
Journal:  Stem Cells Dev       Date:  2012-05-31       Impact factor: 3.272

3.  [Serum-free cultivation of osteoprogenitor cells and osteoblasts to test biomaterials].

Authors:  N Duewelhenke; P Eysel
Journal:  Orthopade       Date:  2007-03       Impact factor: 1.087

4.  Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

Authors:  Ajjai Alva; Susan Slovin; Stephanie Daignault; Michael Carducci; Robert Dipaola; Ken Pienta; David Agus; Kathleen Cooney; Alice Chen; David C Smith; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

Review 5.  Targeting integrins to promote bone formation and repair.

Authors:  Pierre J Marie
Journal:  Nat Rev Endocrinol       Date:  2013-01-29       Impact factor: 43.330

6.  Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation.

Authors:  Maobin Yang; Lorin B Trettel; Douglas J Adams; John R Harrison; Ernesto Canalis; Barbara E Kream
Journal:  Bone       Date:  2010-06-09       Impact factor: 4.398

7.  Effect of blasting treatment and Fn coating on MG63 adhesion and differentiation on titanium: a gene expression study using real-time RT-PCR.

Authors:  M Pegueroles; A Aguirre; E Engel; G Pavon; F J Gil; J A Planell; V Migonney; C Aparicio
Journal:  J Mater Sci Mater Med       Date:  2011-01-22       Impact factor: 3.896

8.  Dentin matrix protein-1 isoforms promote differential cell attachment and migration.

Authors:  Zofia von Marschall; Larry W Fisher
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

9.  The effect of integrin-specific bioactive coatings on tissue healing and implant osseointegration.

Authors:  Timothy A Petrie; Jenny E Raynor; Catherine D Reyes; Kellie L Burns; David M Collard; Andrés J García
Journal:  Biomaterials       Date:  2008-04-11       Impact factor: 12.479

10.  Dexamethasone increases αvβ3 integrin expression and affinity through a calcineurin/NFAT pathway.

Authors:  Jennifer A Faralli; Debjani Gagen; Mark S Filla; Tania N Crotti; Donna M Peters
Journal:  Biochim Biophys Acta       Date:  2013-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.